Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 33,941 shares at $63.83 ($2.2M) on 2021-02-11, disclosed to the SEC on 2021-02-16.
Open-market sale of $2.2M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.79 | 270 | $17K | 0.8% |
| 2 | $62.79 | 414 | $26K | 1.2% |
| 3 | $63.83 | 2,335 | $149K | 6.9% |
| 4 | $63.83 | 1,526 | $97K | 4.5% |
| 5 | $63.83 | 2,335 | $149K | 6.9% |
| 6 | $63.83 | 1,526 |
| $97K |
| 4.5% |
| 7 | $64.87 | 952 | $62K | 2.9% |
| 8 | $64.87 | 952 | $62K | 2.9% |
| 9 | $64.87 | 1,461 | $95K | 4.4% |
| 10 | $64.87 | 1,461 | $95K | 4.4% |
| 11 | $65.80 | 2,418 | $159K | 7.4% |
| 12 | $65.80 | 1,575 | $104K | 4.8% |
| 13 | $65.80 | 2,418 | $159K | 7.4% |
| 14 | $66.65 | 316 | $21K | 1.0% |
| 15 | $66.65 | 206 | $14K | 0.6% |
| 16 | $67.98 | 35 | $2K | 0.1% |
| 17 | $67.99 | 53 | $4K | 0.2% |
| 18 | $60.20 | 833 | $50K | 2.3% |
| 19 | $60.20 | 1,278 | $77K | 3.6% |
| 20 | $60.20 | 1,278 | $77K | 3.6% |
| 21 | $60.20 | 833 | $50K | 2.3% |
| 22 | $61.03 | 1,397 | $85K | 4.0% |
| 23 | $61.03 | 913 | $56K | 2.6% |
| 24 | $61.03 | 913 | $56K | 2.6% |
| 25 | $61.03 | 1,397 | $85K | 4.0% |
| 26 | $62.52 | 985 | $62K | 2.9% |
| 27 | $62.52 | 641 | $40K | 1.9% |
| 28 | $62.52 | 985 | $62K | 2.9% |
| 29 | $63.14 | 814 | $51K | 2.4% |
| 30 | $63.14 | 531 | $34K | 1.6% |
| 31 | $63.14 | 814 | $51K | 2.4% |
| 32 | $63.85 | 46 | $3K | 0.1% |
| 33 | $63.85 | 30 | $2K | 0.1% |
| Total | $63.41 avg | 33,941 | $2.2M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |